Pre-close trading statement

Hikma Pharmaceuticals Plc
27 June 2007



                          Pre-close trading statement

          Hikma expects first half revenue growth of approximately 40%


LONDON, 27 June 2007 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, has seen continuing growth in the
year to date and expects first half revenues to be up approximately 40% and
first half gross margins to be around 50%.

The Branded business, which operates in the Middle East and North Africa (MENA),
has been performing particularly well and is expected to deliver growth of
approximately 60% for the first half, compared to the same period in 2006. This
has been driven by organic growth of approximately 30% and the full
consolidation of JPI, the Saudi-based business that became a wholly owned
subsidiary in the second half of 2006. JPI's integration has now been
successfully completed and it is growing in line with our expectations. The
Branded business's performance in the first half also reflects the continuing
seasonality of this business, which is traditionally strongest in the first six
months of the year.

Underlying growth in the Injectable business should exceed 20% for the first
half, driven by a very strong performance in the MENA region. Including our
recently acquired oncology businesses, Ribosepharm and Thymoorgan, growth in the
Injectable business as a whole is expected to be around 57% for the first half
of the year. The sales and marketing team at Ribosepharm is maintaining its
strong position in the German injectable oncology market and we are successfully
expanding the product portfolio. At Thymoorgan, the injectable oncology
manufacturer we acquired in June, we expect to launch our first product for the
Portuguese market this summer and have already begun the certification of the
plant for the MENA region.

In Portugal, our new cephalosporin plant has recently been approved for
production for Europe and the MENA region and we continue to expect to begin
production for the US market in the second half of the year. As a result of
limited production at the new plant in the year to date, the Injectable business
will see lower operating margins in the first half of the year, compared to the
same period in 2006. As we increase utilisation in the second half, we expect
margins will improve. However, the consolidation of Ribosepharm, with its higher
sales and marketing costs, will lead to a slightly lower Injectables operating
margin for the full year, compared to 2006.

The generic market in the US continues to be competitive, both in volume and
pricing terms. We expect first half sales in the Generic business to be slightly
above the first half of 2006, driven by higher volumes and the contribution from
new product launches. As expected this growth has been achieved through more
competitive pricing.

Outlook

Looking forward, we are confident that we will deliver sales growth in 2007 in
excess of 35%. Gross margin is still expected to be in line with 2006, at around
50%. At the group level, we expect general and administrative expenses to grow
in line with sales, due to the consolidation of acquisitions and the costs
associated with supporting the growth of the Group. Following the acquisitions
of Ribosepharm and Thymoorgan, and including budgeted capital expenditure, we
expect to be in a net debt position of around $85 million at the end of June.

Commenting on the first half, Samih Darwazah, Chairman and CEO said, 'Hikma has
performed well in the year to date. We continue to show growth in our key
businesses and I am confident that, on the back of very solid fundamentals, we
are well-placed to deliver another year of strong growth, in line with our
expectations.'

Hikma will enter its close period on 7 July 2007 ahead of the announcement of
its results for the six months ended 30 June 2007, which will be made on 5
September 2007.

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal                                     [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed          [phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products. Hikma's operates through three
businesses: 'Branded', 'Injectables' and 'Generics', based principally in the
Middle East and North Africa ('MENA'), where it is a market leader and sells
across 18 countries, the United States and Europe. In 2006, Hikma achieved
revenues of $317 million (2005 $262 million) and profit attributable to
shareholders was $55 million (2005 $44 million). At 31 December 2006, the Group
had over 2,400 employees. For news and other information, please visit
www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange